- 0
epocrates
New and updated drugs in epocrates: January 2026
February 2, 2026
Here's a quick roundup of this month's new drug monographs and updates.
New Brand Monographs
- Indication: motion sickness prevention
- Formulation: oral capsule
- Read more: Nereus approved for prevention of motion sickness
- Indication: HSCT-associated thrombotic microangiopathy in adult & pediatric patients ≥2 years
- Formulation: IV injection
- Read more: FDA OKs first treatment for HSCT-associated thrombotic microangiopathy
- Indication: alpha- or beta-thalassemia-associated anemia
- Formulation: TAB: 100 mg
- Read more: FDA greenlights mitapivat for alpha- or beta-thalassemia
Lunsumio Velo (mosunetuzumab-axgb)
- Indication: relapsed or refractory follicular lymphoma
- Formulation: INJ (vial): 5 mg per 0.5 mL, 45 mg per mL for subcutaneous use
- Read more: FDA greenlights subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma
- Indication: Menkes disease in pediatric patients up to 16 years old
- Formulation: INJ for subcutaneous use
- Read more: FDA OKs first treatment for Menkes disease
- Indication: erectile dysfunction
- Formulation: oral strip
New and Expanded Indications
Akeega (niraparib/abiraterone acetate)
- New: metastatic BRCA-mutated prostate cancer – castration-sensitive disease
- Existing: castration-resistant disease
- Read more: Akeega OK’d for BRCA2-mutated metastatic castration-sensitive prostate cancer
- New: uncomplicated gonorrhea in pediatric patients ≥12 years
- Existing: adult patients
- Read more: FDA OKs new oral treatment option for uncomplicated urogenital gonorrhea
Enhertu (fam-trastuzumab deruxtecan-nxki)
- New: HER2-positive breast cancer – first-line treatment
- Existing: HER2-positive progressive disease
- Read more: Enhertu plus pertuzumab OK’d for HER2-positive breast cancer
Recarbrio (imipenem/cilastatin/relebactam)
- New: 1) hospital-acquired or ventilator-associated pneumonia in pediatric patients; 2) complicated intra-abdominal infections in pediatric patients; and 3) complicated urinary tract infection in pediatric patients
- Existing: Same indications in adults
Tecentriq Hybreza (atezolizumab/hyaluronidase-tqjs)
- New: Alveolar soft part sarcoma in pediatric patients ≥12 years
- Existing: Same indication in adults
- New: iron deficiency in pediatric patients ≥10 years
- Existing: iron deficiency in adult patients
- Read more: FDA expands Accrufer approval to include patients 10 years and older
- New: metastatic castration-resistant BRCA-mutated prostate cancer - for patients who have received prior treatment with androgen deprivation therapy
- Existing: metastatic castration-resistant BRCA-mutated prostate cancer - for patients who have received prior treatment with androgen deprivation therapy and taxane-containing chemo
- Read more: Rubraca for metastatic castration-resistant prostate cancer: FDA approval status updated
- New: type 3 Gaucher disease in adult and pediatric patients
- Existing: type 1 Gaucher disease in adult and pediatric patients ≥2 years
- New: 1) schizophrenia in pediatric patients 13 years and older; and 2) manic/mixed bipolar I disorder in pediatric patients ≥10 years
- Existing: 1) schizophrenia in adult patients; and 2) manic/mixed bipolar I disorder in adult patients
Formulation Updates
- New: PELLET: 72 mg, 96 mg, 108 mg, 132 mg per packet
- Existing: CAP: 110 mg, 150 mg
- New: FOAM: 0.05%
- Existing: OINT: 0.05%; CRM: 0.05%
- New: SOL: 0.1%
- Existing: CRM: 0.1%
- New: INJ (pre-filled syringe): 300 mg per 2 mL
- Existing: INJ (pre-filled syringe): 75 mg per 0.5 mL, 150 mg per mL
- New: INJ (pre-filled syringe): 300 mg per 2 mL
- Existing: INJ (pre-filled syringe): 75 mg per 0.5 mL, 150 mg per mL
- New: ER TAB: 450 mg, 750 mg, 900 mg
- Existing: CAP: 100 mg, 300 mg, 400 mg; TAB: 600 mg, 800 mg; ER TAB: 300 mg, 600 mg; SOL: 50 mg per mL
- New: TAB: 30 mg
- Existing: TAB: 60 mg; ER TAB: 180 mg; SOL: 60 mg per 5 mL
- New: CAP: 0.5 mg, 0.75 mg
- Existing: CAP: 1.5 mg, 3 mg, 4.5 mg, 6 mg; CAP (schizophrenia or manic/mixed bipolar disorder 7-day starter pack): 1.5 mg x1 and 3 mg x6
First-time Generics
- Indications: 1) primary and metastatic brain tumors in adult and pediatric patients; and 2) relapsed or refractory Hodgkin lymphoma in adult and pediatric patients
- Equivalent brand: Gleostine
- Indication: type 2 diabetes mellitus
- Equivalent brand: Tradjenta
- Indications: 1) neovascular age-related macular degeneration; 2) retinal vein occlusion-associated macular edema; and 3) myopic choroidal neovascularization
- Equivalent brand: Byooviz (ranibizumab-nuna)
TRENDING THIS WEEK
